vs

Side-by-side financial comparison of Coya Therapeutics, Inc. (COYA) and Datacentrex, Inc. (DTCX). Click either name above to swap in a different company.

Datacentrex, Inc. is the larger business by last-quarter revenue ($7.0M vs $4.0M, roughly 1.8× Coya Therapeutics, Inc.). On growth, Datacentrex, Inc. posted the faster year-over-year revenue change (4463314.1% vs 202768.8%).

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative regulatory T cell (Treg)-based therapies to address unmet medical needs for patients with neurodegenerative, autoimmune, and inflammatory diseases. Its core pipeline includes lead candidates targeting conditions like amyotrophic lateral sclerosis, with primary planned commercial markets across North America and the European Union.

Datacentrex, Inc. is a technology infrastructure service provider offering colocation, managed cloud hosting, and enterprise IT support solutions. It serves small, medium and enterprise clients as well as public sector organizations across North America, focusing on reliable, secure data center operations and customized digital infrastructure services.

COYA vs DTCX — Head-to-Head

Bigger by revenue
DTCX
DTCX
1.8× larger
DTCX
$7.0M
$4.0M
COYA
Growing faster (revenue YoY)
DTCX
DTCX
+4260545.3% gap
DTCX
4463314.1%
202768.8%
COYA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
COYA
COYA
DTCX
DTCX
Revenue
$4.0M
$7.0M
Net Profit
$5.3M
Gross Margin
Operating Margin
87.2%
Net Margin
75.8%
Revenue YoY
202768.8%
4463314.1%
Net Profit YoY
-95.8%
295.3%
EPS (diluted)
$0.65

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
COYA
COYA
DTCX
DTCX
Q4 25
$4.0M
$7.0M
Q3 25
$3.6M
Q3 24
$0
Q2 24
$3.4M
Q4 23
$-374
Q4 22
$-4.1K
Net Profit
COYA
COYA
DTCX
DTCX
Q4 25
$5.3M
Q3 25
$-2.1M
Q3 24
$-4.0M
Q2 24
$-2.9M
Q4 23
$-382.3K
Q4 22
$-712.2K
Operating Margin
COYA
COYA
DTCX
DTCX
Q4 25
87.2%
Q3 25
-68.3%
Q3 24
Q2 24
-94.5%
Q4 23
99467.1%
Q4 22
10408.4%
Net Margin
COYA
COYA
DTCX
DTCX
Q4 25
75.8%
Q3 25
-59.4%
Q3 24
Q2 24
-84.4%
Q4 23
102231.3%
Q4 22
17358.9%
EPS (diluted)
COYA
COYA
DTCX
DTCX
Q4 25
$0.65
Q3 25
$-0.13
Q3 24
$-0.26
Q2 24
$-0.19
Q4 23
$-0.06
Q4 22
$-0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
COYA
COYA
DTCX
DTCX
Cash + ST InvestmentsLiquidity on hand
$46.8M
$38.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$43.0M
$66.2M
Total Assets
$50.0M
$66.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
COYA
COYA
DTCX
DTCX
Q4 25
$46.8M
$38.9M
Q3 25
$28.1M
Q3 24
$31.1M
Q2 24
$36.6M
Q4 23
$259.2K
Q4 22
$1.2M
Stockholders' Equity
COYA
COYA
DTCX
DTCX
Q4 25
$43.0M
$66.2M
Q3 25
$27.3M
Q3 24
$32.0M
Q2 24
$35.3M
Q4 23
$349.3K
Q4 22
$786.5K
Total Assets
COYA
COYA
DTCX
DTCX
Q4 25
$50.0M
$66.8M
Q3 25
$32.0M
Q3 24
$35.6M
Q2 24
$39.9M
Q4 23
$415.2K
Q4 22
$1.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
COYA
COYA
DTCX
DTCX
Operating Cash FlowLast quarter
$-10.7M
$-1.5M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
-0.28×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
COYA
COYA
DTCX
DTCX
Q4 25
$-10.7M
$-1.5M
Q3 25
$-1.1M
Q3 24
$-5.5M
Q2 24
$-4.6M
Q4 23
$-414.8K
Q4 22
$-232.0K
Cash Conversion
COYA
COYA
DTCX
DTCX
Q4 25
-0.28×
Q3 25
Q3 24
Q2 24
Q4 23
Q4 22

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons